Showing results (271-280 of 4,036) with videos related to
Sort By:
Pageof 404
Pharmacoepidemiology and Drug Safety|July 23, 2019
Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillanceSarah C MacDonald, Jacqueline M Cohen, Alice Panchaud, et al.Pharmacoepidemiology and Drug Safety|May 14, 2014
Balancing benefit and risk of medicines: a systematic review and classification of available methodologiesShahrul Mt-Isa, Christine E Hallgreen, Nan Wang, et al.Pharmacoepidemiology and Drug Safety|April 16, 2014
Chronic opioid use emerging after bariatric surgeryMarsha A Raebel, Sophia R Newcomer, Elizabeth A Bayliss, et al.Pharmacoepidemiology and Drug Safety|March 2, 2021
Global COVID-19 pandemic and reporting behavior - An analysis of the Food and Drug Administration adverse events reporting systemMichael Dörks, Kathrin Jobski, Falk Hoffmann, et al.Pharmacoepidemiology and Drug Safety|March 8, 2017
Trends in antipsychotic prescriptions for Japanese outpatients during 2006-2012: a descriptive epidemiological studyKenji Kochi, Izumi Sato, Chika Nishiyama, et al.Pharmacoepidemiology and Drug Safety|March 8, 2017
Six-year multi-centre, observational, post-marketing surveillance of the safety of the HPV-16/18 AS04-adjuvanted vaccine in women aged 10-25 years in KoreaChul-Jung Kim, Rok Song, Jing Chen, et al.Pharmacoepidemiology and Drug Safety|October 31, 2018
Inflation of type I error rates due to differential misclassification in EHR-derived outcomes: Empirical illustration using breast cancer recurrenceYong Chen, Jianqiao Wang, Jessica Chubak, et al.Pharmacoepidemiology and Drug Safety|April 4, 2017
Do patients trust the FDA?: a survey assessing how patients view the generic drug approval processAaron S Kesselheim, Joshua J Gagne, Jessica M Franklin, et al.Pharmacoepidemiology and Drug Safety|April 12, 2017
Effects of expanding the look-back period to all available data in the assessment of covariatesSonja S Nakasian, Jeremy A Rassen, Jessica M FranklinPharmacoepidemiology and Drug Safety|March 5, 2014
Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in JapanTomoko Kurita, Tomomi Kitaichi, Takako Nagao, et al.Pageof 404